313 related articles for article (PubMed ID: 35401817)
41. Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
Yeh IJ; Esakov E; Lathia JD; Miyagi M; Reizes O; Montano MM
Sci Rep; 2019 Nov; 9(1):17663. PubMed ID: 31776402
[TBL] [Abstract][Full Text] [Related]
42. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
Cho TM; Kim JY; Kim YJ; Sung D; Oh E; Jang S; Farrand L; Hoang VH; Nguyen CT; Ann J; Lee J; Seo JH
Cancer Lett; 2019 Apr; 447():141-153. PubMed ID: 30703411
[TBL] [Abstract][Full Text] [Related]
43. Long non-coding RNA CCAT2 promotes oncogenesis in triple-negative breast cancer by regulating stemness of cancer cells.
Xu Z; Liu C; Zhao Q; Lü J; Ding X; Luo A; He J; Wang G; Li Y; Cai Z; Wang Z; Liu J; Liu S; Li W; Yu Z
Pharmacol Res; 2020 Feb; 152():104628. PubMed ID: 31904506
[TBL] [Abstract][Full Text] [Related]
44. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
45. ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway.
Nguyen K; Yan Y; Yuan B; Dasgupta A; Sun J; Mu H; Do KA; Ueno NT; Andreeff M; Battula VL
Mol Cancer Ther; 2018 Dec; 17(12):2689-2701. PubMed ID: 30237308
[TBL] [Abstract][Full Text] [Related]
46. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
[TBL] [Abstract][Full Text] [Related]
47. The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes.
Cuyàs E; Gumuzio J; Verdura S; Brunet J; Bosch-Barrera J; Martin-Castillo B; Alarcón T; Encinar JA; Martin ÁG; Menendez JA
Aging (Albany NY); 2020 Mar; 12(6):4794-4814. PubMed ID: 32191225
[TBL] [Abstract][Full Text] [Related]
48. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
[TBL] [Abstract][Full Text] [Related]
49. NDR1 increases NOTCH1 signaling activity by impairing Fbw7 mediated NICD degradation to enhance breast cancer stem cell properties.
Wang LL; Wan XY; Liu CQ; Zheng FM
Mol Med; 2022 May; 28(1):49. PubMed ID: 35508987
[TBL] [Abstract][Full Text] [Related]
50. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
[TBL] [Abstract][Full Text] [Related]
51. KDM4 Inhibition Targets Breast Cancer Stem-like Cells.
Metzger E; Stepputtis SS; Strietz J; Preca BT; Urban S; Willmann D; Allen A; Zenk F; Iovino N; Bronsert P; Proske A; Follo M; Boerries M; Stickeler E; Xu J; Wallace MB; Stafford JA; Kanouni T; Maurer J; Schüle R
Cancer Res; 2017 Nov; 77(21):5900-5912. PubMed ID: 28883001
[TBL] [Abstract][Full Text] [Related]
52. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
[TBL] [Abstract][Full Text] [Related]
53. Epigenetic regulation of pluripotency inducer genes NANOG and SOX2 in human prostate cancer.
Niharika ; Roy A; Mishra J; Chakraborty S; Singh SP; Patra SK
Prog Mol Biol Transl Sci; 2023; 197():241-260. PubMed ID: 37019595
[TBL] [Abstract][Full Text] [Related]
54. Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer.
Feng W; Li Y; Chu J; Li J; Zhang Y; Ding X; Fu Z; Li W; Huang X; Yin Y
Cancer Med; 2018 Oct; 7(10):5130-5144. PubMed ID: 30239174
[TBL] [Abstract][Full Text] [Related]
55. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Zheng Q; Fan H; Meng Z; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):897-904. PubMed ID: 30060056
[TBL] [Abstract][Full Text] [Related]
56. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
57. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
Tian J; Raffa FA; Dai M; Moamer A; Khadang B; Hachim IY; Bakdounes K; Ali S; Jean-Claude B; Lebrun JJ
Br J Cancer; 2018 Dec; 119(12):1495-1507. PubMed ID: 30482914
[TBL] [Abstract][Full Text] [Related]
58. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
59. BTF3 promotes stemness and inhibits TypeⅠInterferon signaling pathway in triple-negative breast cancer.
Wang H; Gao L; Qi M; Su P; Xiong X; Zhao J; Hu J; Han B
Biochem Biophys Res Commun; 2021 Jan; 537():22-28. PubMed ID: 33383560
[TBL] [Abstract][Full Text] [Related]
60. Lysophosphatidic Acid Promotes the Expansion of Cancer Stem Cells via TRPC3 Channels in Triple-Negative Breast Cancer.
Hirata N; Yamada S; Yanagida S; Ono A; Yasuhiko Y; Nishida M; Kanda Y
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
